BRPI0415637A - derivados de sulfoalquil éter-alquil éter ciclodextrina - Google Patents

derivados de sulfoalquil éter-alquil éter ciclodextrina

Info

Publication number
BRPI0415637A
BRPI0415637A BRPI0415637-4A BRPI0415637A BRPI0415637A BR PI0415637 A BRPI0415637 A BR PI0415637A BR PI0415637 A BRPI0415637 A BR PI0415637A BR PI0415637 A BRPI0415637 A BR PI0415637A
Authority
BR
Brazil
Prior art keywords
sae
ether
cyclodextrin
membrane
alkyl
Prior art date
Application number
BRPI0415637-4A
Other languages
English (en)
Inventor
Valentino J Stella
Serena Tongiani
Original Assignee
Univ Kansas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Kansas filed Critical Univ Kansas
Publication of BRPI0415637A publication Critical patent/BRPI0415637A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Detergent Compositions (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"DERIVADOS DE SULFOALQUIL éTER-ALQUIL éTER CICLODEXTRINA". A presente invenção refere-se a um derivado de sulfoalquil éter-alquil éter ciclodextrina (SAE-AE-CD) é provido. A SAE-AE-CD possui vantagens sobre derivados de SAE-CD e AE-CD conhecidos bem como outra ciclodextrina de origem ao ser mais solúvel em água e perturbar menos a membrana. A SAE-AE-CD inclui pelo menos um grupo sulfoalquil éter e pelo menos um grupo alquil éter mesmo que o grau de substituição para os grupos funcionais seja diferente. O grupo SAF funcional pode estar presente em excesso molar sobre o grupo funcional de AE e vice versa. O grau total de substituição da ciclodextrina, com relação a ambos grupos funcionais, pode ser variado de modo que uma maioria ou minoria das porções hidroxila da CD é derivatizada. O derivado de SAE-AE-CD pode ser usado para solubilizar compostos com solubilidade insuficiente em água. Em alguns casos, eles também solubilizam compostos em solução contra degracação ou solubilizam produtos de degradação formados durante a degradação. Ainda, SAE-AE-CD pode ser também usada para outros propósitos tal como agentes osmóticos, agentes usados para mascarar o gosto de drogas problemáticas. Surpreendentemente, embora AE-CDs sejam sabidas ser tóxicas ao perturbarem membrana, as SAE-AE-CDs perturbam menos a membrana e então têm maior segurança.
BRPI0415637-4A 2003-10-31 2004-10-29 derivados de sulfoalquil éter-alquil éter ciclodextrina BRPI0415637A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51602203P 2003-10-31 2003-10-31
PCT/US2004/036097 WO2005042584A2 (en) 2003-10-31 2004-10-29 Sulfoalkyl ether-alkyl ether cyclodextrin derivatives

Publications (1)

Publication Number Publication Date
BRPI0415637A true BRPI0415637A (pt) 2006-12-12

Family

ID=34549474

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0415637-4A BRPI0415637A (pt) 2003-10-31 2004-10-29 derivados de sulfoalquil éter-alquil éter ciclodextrina

Country Status (10)

Country Link
US (1) US7625878B2 (pt)
EP (1) EP1678211A4 (pt)
JP (1) JP2007523887A (pt)
KR (1) KR20060096490A (pt)
CN (1) CN101039682A (pt)
AU (1) AU2004285032A1 (pt)
BR (1) BRPI0415637A (pt)
CA (1) CA2543443A1 (pt)
RU (1) RU2006118802A (pt)
WO (1) WO2005042584A2 (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
AU2005237523A1 (en) 2004-04-23 2005-11-10 Cydex Pharmaceuticals, Inc. DPI formulation containing sulfoalkyl ether cyclodextrin
AU2013201437B2 (en) * 2004-04-23 2015-09-03 Cydex Pharmaceuticals, Inc DPI formulation containing sulfoalkyl ether cyclodextrin
DK2952197T3 (en) * 2005-10-26 2017-08-07 Cydex Pharmaceuticals Inc SULPHALYCYLETER CYCLE CODE EXTRACTION COMPOSITION AND PROCEDURE FOR PREPARING THEREOF
US7629331B2 (en) 2005-10-26 2009-12-08 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
CN100503647C (zh) 2005-11-02 2009-06-24 南京师范大学 羟丙基-磺丁基-β-环糊精及其制备方法、分析方法以及在药学上的应用
CN100486645C (zh) * 2006-09-12 2009-05-13 南京师范大学 含有环糊精紫杉醇包合物的药物组合物及其制备方法
CN100411688C (zh) * 2006-09-12 2008-08-20 南京师范大学 含有环糊精/多烯紫杉醇包合物的药物组合物及其制备方法
US20090239942A1 (en) 2006-09-15 2009-09-24 Cloyd James C Topiramate Compositions and Methods of Making and Using the Same
ES2493641T3 (es) * 2007-06-28 2014-09-12 Cydex Pharmaceuticals, Inc. Administración nasal de soluciones acuosas de corticosteroides
US7635773B2 (en) * 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
US8492538B1 (en) 2009-06-04 2013-07-23 Jose R. Matos Cyclodextrin derivative salts
US11357728B2 (en) 2009-10-26 2022-06-14 Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. Liposome having inner water phase containing sulfobutyl ether cyclodextrin salt
US10603287B2 (en) 2016-07-20 2020-03-31 Ptlnv, Llc, Series Three (3) Albumin nanosphere preparations to control bleeding from surgical operations
US11260109B2 (en) 2010-11-16 2022-03-01 Richard C. K. Yen Albumin nanoparticles to augment stem cell function in vivo
US9351925B2 (en) * 2011-09-10 2016-05-31 Richard C. K. Yen Submicron particles to decrease transfusion
US11260110B2 (en) 2009-11-18 2022-03-01 Ptlnv, Llc, Series Four (4) Nanoparticles for the therapeutic treatment of radiation-induced skin ulcers
DE102010012281A1 (de) 2010-03-22 2011-09-22 Fresenius Medical Care Deutschland Gmbh Pharmazeutische Zusammensetzungen enthaltend substituiertes 6-Deoxy-6-sulfanylcyclodextrin
CN104271605B (zh) 2012-02-15 2017-07-25 锡德克斯药物公司 环糊精衍生物的制造方法
JP2015508846A (ja) 2012-02-28 2015-03-23 サイデックス・ファーマシューティカルズ・インコーポレイテッド アルキル化シクロデキストリン組成物ならびにその調製方法および使用方法
BR112015008954B1 (pt) 2012-10-22 2021-03-02 Cydex Pharmaceuticals, Inc processos para preparar uma composição de ciclodextrina alquilatada compreendendo uma ciclodextrina alquilatada, para preparar pelo menos 9 lotes consecutivos da mesma e para preparar uma composição farmacêutica
WO2014122498A2 (en) * 2012-12-24 2014-08-14 Supratek Pharma Inc. Cabazitaxel composition
CN103554307B (zh) * 2013-09-25 2017-01-11 南京师范大学 羧甲基‑羟丙基‑β‑环糊精及其制备方法
FI3183295T3 (fi) 2014-08-22 2023-09-25 Cydex Pharmaceuticals Inc Fraktioidut alkyloidut syklodekstriinikoostumukset ja menetelmät niiden valmistamiseksi ja käyttämiseksi
CA2980170A1 (en) 2015-03-19 2016-09-22 Cydex Pharmaceuticals, Inc. Compositions containing silymarin and sulfoalkyl ether cyclodextrin and methods of using the same
US20170007617A1 (en) 2015-07-09 2017-01-12 Gilead Sciences Drive Intravenous formulations of a late sodium current inhibitor
US20180280537A1 (en) * 2015-10-07 2018-10-04 Uti Limited Partnership Multifunctional polyanionic cyclodextrin dendrimers
WO2017194385A1 (en) 2016-05-09 2017-11-16 Xellia Pharmaceuticals Aps Stabilized glycopeptide antibiotic formulations
KR102500936B1 (ko) * 2016-07-22 2023-02-16 에꼴 뽈리떼끄닉 뻬데랄 드 로잔느 (으뻬에프엘) 살바이러스 화합물 및 이의 용도
CN106519080A (zh) * 2017-01-10 2017-03-22 长沙理工大学 一种γ‑环糊精‑丙酸包合物及其制备方法
EP3618825A4 (en) 2017-05-03 2021-01-20 Cydex Pharmaceuticals, Inc. COMPOSITION CONTAINING CYCLODEXTRIN AND BUSULFAN
CN111093627B (zh) 2017-07-11 2024-03-08 吉利德科学公司 用于治疗病毒感染的包含rna聚合酶抑制剂和环糊精的组合物
WO2021041505A1 (en) * 2019-08-26 2021-03-04 Forman, Mervyn B. Medical devices for continuous delivery of therapeutic agents
CN111393543A (zh) * 2020-05-20 2020-07-10 黑龙江八一农垦大学 环糊精衍生物、环糊精衍生物包覆的除草剂及制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0146841A3 (de) * 1983-12-17 1986-11-20 Consortium für elektrochemische Industrie GmbH Wasserlösliche Mischether des beta-Cyclodextrins und ein Verfahren zu ihrer Herstellung
US5658894A (en) 1989-04-23 1997-08-19 The Trustees Of The University Of Pennsylvania Compositions for inhibiting restenosis
US5019562A (en) 1988-01-19 1991-05-28 The Trustees Of The University Of Pennsylvania/Childrens Hospital Corporation Growth inhibiting agent and the use thereof
US5183809A (en) 1990-02-15 1993-02-02 The Trustees Of The University Of Pennsylvania/Childrens Hospital Corporation Cyclodextrin polymers and cyclodextrins immobilized on a solid surface
US5760015A (en) 1988-01-19 1998-06-02 The Trustees Of The University Of Pennsylvania Cyclodextrin compounds and methods of making and use thereof
DE69127256T2 (de) 1990-05-21 1998-02-12 Toppan Printing Co Ltd Cyclodextrinderivat
DE4428654A1 (de) 1994-08-12 1996-02-15 Consortium Elektrochem Ind Wasserlösliche Cyclodextrinderivate mit lipophilen Substituenten und Verfahren zu ihrer Herstellung
DK0889056T3 (da) * 1997-07-01 2006-07-17 Pfizer Prod Inc Process for making a cyclodextrin
US6316613B1 (en) * 1997-07-25 2001-11-13 Beckman Coulter, Inc. Chiral separation of pharmaceutical compounds with charged cyclodextrins using capillary electrophoresis
TWI242015B (en) 1999-11-29 2005-10-21 Akzo Nobel Nv 6-mercapto-cyclodextrin derivatives: reversal agents for drug-induced neuromuscular block
US6479467B1 (en) * 1999-12-16 2002-11-12 Eastman Chemical Company Cyclodextrin ethers
AU2002241823A1 (en) * 2001-01-11 2002-07-24 Eastman Chemical Company Cyclodextrin sulfonates, guest inclusion complexes, methods of making the same and related materials

Also Published As

Publication number Publication date
CA2543443A1 (en) 2005-05-12
WO2005042584A2 (en) 2005-05-12
US7625878B2 (en) 2009-12-01
CN101039682A (zh) 2007-09-19
US20060258537A1 (en) 2006-11-16
WO2005042584A3 (en) 2007-06-07
EP1678211A4 (en) 2008-04-02
KR20060096490A (ko) 2006-09-11
RU2006118802A (ru) 2007-12-10
EP1678211A2 (en) 2006-07-12
JP2007523887A (ja) 2007-08-23
AU2004285032A1 (en) 2005-05-12

Similar Documents

Publication Publication Date Title
BRPI0415637A (pt) derivados de sulfoalquil éter-alquil éter ciclodextrina
KR101062068B1 (ko) 유착방지용 조성물
BRPI0711620A2 (pt) misturas poliméricas de polissacarídeos aniônicos e catiônicos e uso destas
ES2269943T5 (es) Polímeros solubles de glucosa altamente ramificados y su procedimiento de obtención
BRPI0116945B8 (pt) preparado para tratamento local de epitélio hiperproliferativo
AU2001275651A1 (en) Curcumin derivatives with improved water solubility compared to curcumin and medicaments containing the same
BRPI0414017B8 (pt) pró-fármaco polimérico de múltiplos braços, composição farmacêutica e método para a preparação de um pró-fármaco polimérico de múltiplos braços.
AR021013A1 (es) Composicion para encolado de papel y metodos para tratar el papel, y papel obtenido con dicha composicion
AR023717A1 (es) Composicion que contiene polimeros solubles en agua, dispersales, proceso para mejorar la dispersabilidad en agua
AR047205A1 (es) Composiciones oftalmicas que contienen una combinacion sinergica de tres polimeros
GB2491491A (en) Improved anaesthetic formulations comprising neuroactive steroids
BRPI0809891C8 (pt) dispensador, produto e composições de espuma higienizante
BRPI9906372B8 (pt) composição farmaceutica aquosa para aplicação na mucosa
NZ624749A (en) A sulfated polysaccharide compound and the preparation and use thereof
YU75403A (sh) Vodeni amfotericin b preparat
WO2023275046A1 (en) Transparent cosmetic composition with ascorbic acid, a cationic polymer and a glycol
BR0009684A (pt) Composição de engomadura
JP2013523864A (ja) アセトアミノフェン組成物
WO2007100822A3 (en) Fluvastatin sodium pharmaceutical compositions
AU2016296216B2 (en) Peritoneal therapeutic fluid
CA2560432A1 (en) Pseudo-thermosetting neutralized chitosan composition forming a hydrogel and a process for producing the same
ES2734582T3 (es) Composición acuosa para cápsula dura, y cápsula dura producida utilizando la misma
KR930021206A (ko) 시타라빈 옥포스페이트 경질 캡슐제
JP2011502169A5 (pt)
BRPI0520078A2 (pt) composição contendo quitosana para liberação sustentada de drogas

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.